These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 20578237)

  • 1. Sickle cell anemia and vascular dysfunction: the nitric oxide connection.
    Akinsheye I; Klings ES
    J Cell Physiol; 2010 Sep; 224(3):620-5. PubMed ID: 20578237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC; Granger DN
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial function and hypertension.
    Landmesser U; Drexler H
    Curr Opin Cardiol; 2007 Jul; 22(4):316-20. PubMed ID: 17556884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sickle cell disease at the dawn of the molecular era.
    Abboud MR; Musallam KM
    Hemoglobin; 2009; 33 Suppl 1():S93-S106. PubMed ID: 20001639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.
    Hebbel RP
    Am J Hematol; 2011 Feb; 86(2):123-54. PubMed ID: 21264896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences.
    Aslan M; Freeman BA
    Cell Mol Biol (Noisy-le-grand); 2004 Feb; 50(1):95-105. PubMed ID: 15040433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice.
    Virdis A; Iglarz M; Neves MF; Amiri F; Touyz RM; Rozen R; Schiffrin EL
    Arterioscler Thromb Vasc Biol; 2003 Aug; 23(8):1352-7. PubMed ID: 12829522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
    Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide metabolism and the acute chest syndrome of sickle cell anemia.
    Sullivan KJ; Kissoon N; Gauger C
    Pediatr Crit Care Med; 2008 Mar; 9(2):159-68. PubMed ID: 18477929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.
    Conran N; Franco-Penteado CF; Costa FF
    Hemoglobin; 2009; 33(1):1-16. PubMed ID: 19205968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of vasculopathy in sickle cell disease and thalassemia.
    Morris CR
    Hematology Am Soc Hematol Educ Program; 2008; ():177-85. PubMed ID: 19074078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?
    Morris CR; Morris SM; Hagar W; Van Warmerdam J; Claster S; Kepka-Lenhart D; Machado L; Kuypers FA; Vichinsky EP
    Am J Respir Crit Care Med; 2003 Jul; 168(1):63-9. PubMed ID: 12626350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in clinical research in sickle cell disease.
    Hagar W; Vichinsky E
    Br J Haematol; 2008 May; 141(3):346-56. PubMed ID: 18341629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function.
    Meyer C; Heiss C; Drexhage C; Kehmeier ES; Balzer J; Mühlfeld A; Merx MW; Lauer T; Kühl H; Floege J; Kelm M; Rassaf T
    J Am Coll Cardiol; 2010 Feb; 55(5):454-9. PubMed ID: 20117459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.
    Villagra J; Shiva S; Hunter LA; Machado RF; Gladwin MT; Kato GJ
    Blood; 2007 Sep; 110(6):2166-72. PubMed ID: 17536019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oxidant stress and endothelial dysfunction].
    Markov KhM
    Patol Fiziol Eksp Ter; 2005; (4):5-9. PubMed ID: 16408656
    [No Abstract]   [Full Text] [Related]  

  • 19. Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.
    Deonikar P; Kavdia M
    J Appl Physiol (1985); 2012 Apr; 112(8):1383-92. PubMed ID: 22223452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.
    Kaul DK; Zhang X; Dasgupta T; Fabry ME
    Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H39-47. PubMed ID: 18456737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.